

Remarks

Upon entry of the foregoing amendment, claims 38-210 are pending in the application, with 38, 62, 91, 114, 141, 169, and 190 as the independent claims. Claims 1-37 have been cancelled without prejudice to or disclaimer of the subject matter therein. New claims 38-210 have been added. It is believed that these changes introduce no new matter, and their entry is respectfully requested.

Support for the new claims can be found throughout the specification. For the Examiner's convenience, **Table 1** (attached) sets out examples of locations where support for the new claims can be found in the present application and priority Appl. Nos. 08/159,184, 08/278,634, and 08/103,396. Applicants will provide examples of locations where support may be found in the other priority applications at a later time, if the Examiner so wishes.

Applicants also provide in **Table 2** (attached), a list of each peptide recited in the claims (those recited in the independent claims are indicated by claim number), the peptide number and identity of the prostate antigen where the peptide is found, and the filing date and serial number of the application in which the peptide was first disclosed by Applicants.

The specification has been amended to change the cross-reference to related applications and to incorporate material from the priority applications, such as Appl. No. 08/159,184, filed November 29, 1993, which were incorporated into the original application.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date: March 26, 2002

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

::ODMA\MHODMA\SKGF_DC1;38316;1

SKGF Rev.1 1/26/01 mac

Version with markings to show changes made

In the Specification:

The paragraph beginning on page 1, line 8 has been replaced with the following two paragraphs:

This application claims priority to Provisional Appl. No. 60/171,312, filed December 21, 1999 (147.00 US), which is incorporated herein by reference; and is a continuation in part (CIP) of International Appl. No. PCT/US00/17842, filed June 28, 2000, which published in English under PCT Article 21(2) (134.40 PC); and is a CIP of Appl. No. 09/017,743, filed February 3, 1998 (80.50 US); and is a CIP of Appl. No. 09/017,524, filed February 3, 1998 (50.91 US); and is a CIP of Appl. No. 08/454,033, filed May 26, 1995 (58.50 US); and is a CIP of Appl. No. 08/347,610, filed December 1, 1994 (50.50 US); and is a CIP of Appl. No. 08/344,824, filed November 23, 1994 (80.10 US); and is a CIP of Appl. No. 08/205,713, filed March 4, 1994 (58.30 US); said PCT/US00/17842 (134.40 PC) claims priority to Provisional Application No. 60/141,422, filed June 29, 1999; said Appl. No. 09/017,743 (80.50 US) is a CIP of Appl. No. 08/590,298, filed January 23, 1996, abandoned (80.30 US); said Appl. No. 09/017,524 (50.91 US) is a CIP of Appl. No. 08/589,107, filed January 23, 1996, abandoned (50.70 US); said Appl. No. 08/347,610 (50.50 US) is a CIP of Appl. No. 08/159,339, filed November 29, 1993, U.S. Patent No. 6,037,135 (50.30 US), which is a CIP of Appl. No. 08/103,396, filed August 6, 1993, abandoned (50.20 US), which is a CIP of Appl. No. 08/027,746, filed March 5, 1993, abandoned (50.10 US), which is a CIP of Appl. No. 07/926,666, filed August 8, 1992, abandoned (50.00 US); said Appl. No. 08/344,824 (80.10 US) is a CIP of Appl. No. 08/278,634, filed July 21, 1994, abandoned (80.00 US); said Appl. No. 08/205,713 (58.30 US) is a CIP of Appl. No. 08/159,184, filed November 29, 1993, abandoned (58.20 US), which is a CIP of Appl. No. 08/073,205, filed June 4, 1993, abandoned (58.10 US), which is a CIP of Appl. No. 08/027,146, filed March 5,

1993, abandoned (58.00 US) claims the benefit of claims priority to provisional application 60/171,312 filed 12/21/99.

This application is related to U.S.S.N. 09/189,702, filed 11/10/98, which is a CIP of U.S.S.N. 08/205,713 filed 3/4/94, which is a CIP of abandoned U.S.S.N. 08/159,184 filed 11/29/93, which is a CIP of abandoned U.S.S.N. 08/073,205 filed 6/4/93 which is a CIP of abandoned U.S.S.N. 08/027,146 filed 3/5/93. The present application is also related to U.S.S.N. 09/226,775, which is a CIP of abandoned U.S.S.N. 08/815,396, which claims benefit of abandoned U.S.S.N. 60/013,113. Furthermore, the present application is related to U.S.S.N. 09/017,735, which is a CIP of abandoned U.S.S.N. 08/589,108; U.S.S.N. 08/454,033; and U.S.S.N. 08/349,177. The present application is also related to U.S.S.N. 09/017,524, U.S.S.N. 08/821,739, which claims benefit of abandoned U.S.S.N. 60/013,833; and U.S.S.N. 08/347,610, which is a CIP of U.S.S.N. 08/159,339, which is a CIP of abandoned U.S.S.N. 08/103,396, which is a CIP of abandoned U.S.S.N. 08/027,746, which is a CIP of abandoned U.S.S.N. 07/926,666. The present application is also related to U.S.S.N. 09/017,743, which is a CIP of abandoned U.S.S.N. 08/590,298; and U.S.S.N. 08/452,843, which is a CIP of U.S.S.N. 08/344,824, which is a CIP of abandoned U.S.S.N. 08/278,634. The present application is also related to PCT application 99/12066 filed 5/28/99 which claims benefit of provisional U.S.S.N. 60/087,192, and U.S.S.N. 09/009,953, which is a CIP of abandoned U.S.S.N. 60/036,713 and abandoned U.S.S.N. 60/037,432. In addition, the present application is related to U.S.S.N. 09/098,584, U.S.S.N. 09/239,043, U.S.S.N. 60/117,486, U.S.S.N. 09/350,401, and U.S.S.N. 09/357,737. In addition, the present application is related to U.S. Patent Application entitled "Inducing Cellular Immune Responses to Carcinoembryonic Antigen Using Peptide and Nucleic Acid Compositions", Attorney Docket No. 018623-014400, filed 12/10/99; U.S. Patent Application entitled "Inducing Cellular Immune Responses to p53 Using Peptide and Nucleic Acid Compositions"; Attorney Docket No. 018623-014500, filed 12/10/99; U.S. Patent Application entitled "Inducing Cellular Immune Responses to MAGE2/3 Using Peptide and Nucleic Acid Compositions", Attorney Docket No. 018623-014600, filed 12/10/99; and U.S. Patent Application entitled "Inducing Cellular Immune Responses to HER2/neu Using

Peptide and Nucleic Acid Compositions", Attorney Docket No. 018623-014800, filed 12/10/99. All of the above applications are incorporated herein by reference.

The paragraph beginning at page 15, line 1 has been replaced with the following paragraph:

The term "peptide" is used interchangeably with "oligopeptide" in the present specification to designate a series of residues, typically L-amino acids, connected one to the other, typically by peptide bonds between the α -amino and carboxyl groups of adjacent amino acids. The preferred CTL-inducing peptides of the invention are less than about 15 residues in length, and are often 13 residues or less in length and usually consist of between about 8 and about 11 residues, preferably 9 or 10 residues. The preferred HTL-inducing oligopeptides are less than about 50 residues in length and usually consist of between about 6 and about 30 residues, more usually between about 12 and 25, and often between about 15 and 20 residues.

In the Claims:

Claims 1-37 have been cancelled.

Claims 38-210 have been added.

Table 1- Example of Support for Claims

<u>Claim Language</u>	<u>This Application</u>	<u>Appl. No.</u> <u>08/278,634</u>	<u>Appl. No.</u> <u>08/103,396</u>	<u>Appl. No.</u> <u>08/159,184</u>
T helper peptide	p.53, lines 32-34; p.54, lines 4-28	p. 14, lines 27-33; p.15, lines 8-12	p.22, lines 18-33	p.19, lines 22-38; p.20, lines 1-2
Spacer	p.49, lines 16-20; p.54, lines 5-12; p.84, line 10	p.14, lines 32-33; p. 15 lines 1-5	p.22, lines 21-36	p.19, lines 22,31
Carrier	p.15, lines 11-13; p.46, lines 24-27; p.59, lines 12-14	p.21, lines 14-22	p.29, lines 27-38	p.26, lines 36-38; p.27, lines 1-2
Lipid	p.46, lines 31-33; p.52, lines 22-25; p.55, lines 14-17	p.15, lines 13-23	p.23, lines 1-16	p.20, lines 3-24; p.25, lines 20-24
Fusion protein	p.41, line 9-13; p.57, lines 13-15	p.16, lines 24-25	p. 24, lines 25-28	p.21, lines 26-29
Liposome	p.60, lines 3-19	p.15, lines 18-20; p.20, lines 3-20	p.28, lines 1-26	p.25, lines 3-28
Pharmaceutically acceptable carrier	p.15, lines 9-10; p.59 line 14	p.18, lines 29-33	p.27, lines 10-31	p.24, lines 11-21
Linker	p.41, lines 7-9; p.85, lines 16-17	p.15, lines 8-9; p.16, lines 30-32	p.24, lines 34-38	p.21, line 36
Homopolymer/ heteropolymer	p.46, lines 16-17	p.21 lines 14-16	p.29, lines 27-29	p.19, line 30
Less than 15 amino acids in length		p.2, lines 31-33	p.4, line 15	p.4, line 31
8, 9, 10, or 11 amino acids in length	p.15, lines 5-6	p.2, lines 31-33	p.4, lines 16-17	p.4, line 5; p.4, lines 31-32

Table 2-Peptides					
Claim	Sequence	Source	Peptide #	Priority Appl. No.	Priority Appl. Date
38	VSHSFPHPLY	PSA	2.0157	07/926,666	8/7/1992
38	LTAAHCIRNK	PSA	1.0653	07/926,666	8/7/1992
38	YTKVVHYRK	PSA	1.0272	07/926,666	8/7/1992
62	LSELSLLSLY	PAP	3.0237	08/103,396	8/6/1993
62	ASCHLTELY	PAP	3.0166	08/103,396	8/6/1993
62	KGEYFVEMYY	PAP	3.0238	08/103,396	8/6/1993
62	LYCESVHNF	PAP	3.016	08/103,396	8/6/1993
62	PYKDFIATL	PAP	3.0159	08/103,396	8/6/1993
62	LYFEKGEYF	PAP	3.0161	08/103,396	8/6/1993
62	ATQIPSYKK	PAP	3.0158	08/103,396	8/6/1993
62	SLYTKVVHYR	PSA	1098.11	08/103,396	8/6/1993
91	FLTPKKLQCV	PSA.161	1098.02	08/027,146	3/5/1993
91	KLQCVDLHV	PSA.166	990.01	08/027,146	3/5/1993
114	HSFPHPLY	PSA	3.0358	08/159,339	11/29/1993
114	ALGTTCYA	PSA.143	1166.07	08/159,184	11/29/1993
114	VLAKELKFV*	PAP.30	1097.171	08/159,184	11/29/1993
114	ILLWQPIPV	PAP.135	1044.041	08/159,184	11/29/1993
114	IMYSAHDTTV	PAP.284	1097.052	08/159,184	11/29/1993
114	LLFFWLDRSV	PAP.21	1097.04	08/159,184	11/29/1993
141	HPLYDMSLL	PSA	19.0076	08/590,298	1/23/1996
141	FPHPLYDMSL	PSA	20.018	08/590,298	1/23/1996
141	SLLSLYGIHK	PAP	20.0219	08/589,107	1/23/1996
141	HLTELYFEK	PAP	20.0065	08/589,107	¹ 1/23/1996

* Elected peptide

141	NPILLWQPI	PAP	19.0083	08/590,298	² 1/23/1996
141	IPSYKKLIM	PAP	19.0086	08/590,298	³ 1/23/1996
141	CPLERFAEL	PAP	19.0089	08/590,298	1/23/1996
169	HPQWVLTA	PSA	1166.27	08/278,634	7/21/1994
190	TLMSAMTNL	PAP.112	1177.01	08/454,033	5/26/1995